The purpose of this study is to prioritize key environmental sustainability dimensions and indicators within the pharmaceutical sector to support informed decision-making and policy formulation. The study adopts a quantitative methodology using RIDIT analysis to compare multiple sustainability indicators against a reference distribution and derive priority rankings. Survey data collected from 516 respondents were analyzed across environmental impact, environmental sustainability, impact investing, and adoption of green pharmaceutical practices. The findings reveal that environmental sustainability and environmental impact indicators receive the highest priority, indicating strong stakeholder emphasis on long-term ecological outcomes. Impact investing plays a moderate facilitative role, while green practice adoption ranks lowest, highlighting implementation gaps. The study offers practical implications for policymakers and industry managers by identifying areas requiring targeted interventions and resource allocation. The novelty of this research lies in the application of RIDIT analysis to systematically rank sustainability dimensions in the pharmaceutical context, providing a robust and interpretable prioritization framework.
